Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

3.435 +0.145 (+4.41%)
Delayed Quote Updated: 1:39 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21,338
Open 3.310
Bid (Size) 3.370 (100)
Ask (Size) 3.500 (200)
Prev. Close 3.290
Today's Range 3.310 - 3.500
52wk Range 3.200 - 9.821
Shares Outstanding 41,957,197
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire

Performance

52-Week Range 65.0% below 52-week high
3.435
3.2052W Low 9.8252W High
1 Week 5.1% below 1-week high
3.201W Low 3.621W High

Verrica Pharmaceuticals Inc. - Common Stock (VRCA) traded between $3.20 and $9.82 over the past 52 weeks and last traded at $3.44, 65.0% below its 52-week high. Over the past week it ranged between $3.20 and $3.62.

Past 12 Months
-1.3%
-20.3%
-36.5%
-52.0%
-58.6%
-3.5%
1W -$0.04
1M -$0.87
3M -$1.98
6M -$3.73
YTD -$4.87
1Y -$0.12

VRCA was -3.5% over the past year, -52.0% over six months, -58.6% year to date, -1.3% in the last week.

12 Months vs Market
VRCA
-3.5%
DIA
+12.4%
SPY
+12.4%
QQQ
+10.1%
IWM
+15.6%

Over the past 12 months VRCA returned -3.5% versus DIA (Dow) +12.4%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +10.1% and IWM (Russell 2000) +15.6%.

Volume & Liquidity 0.30× 3-mo avg
Today 21,338 3-mo avg 70.0K
1W
37.3K
1M
52.7K
3M
70.0K
6M
61.3K
YTD
87.0K
1Y
118.0K

VRCA most recently traded 21,338 shares against a 3-month average daily volume of 70.0K.

More News

Read More
News headline image
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
Verrica Pharmaceuticals (NASDAQ:VRCA) Q1 Results Beat Revenue Estimates as Pipeline Progress and Record Demand Drive Positive Momentum ↗
Via Chartmill
News headline image
Verrica (VRCA) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Verrica Pharmaceuticals Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica (VRCA) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
From The Rosen Law Firm, P.A.
Via Business Wire

Frequently Asked Questions

Is Verrica Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, Verrica Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does Verrica Pharmaceuticals Inc. - Common Stock trade on?
Verrica Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock?
The ticker symbol for Verrica Pharmaceuticals Inc. - Common Stock is VRCA on the Nasdaq Stock Market
What is the current price of Verrica Pharmaceuticals Inc. - Common Stock?
The current price of Verrica Pharmaceuticals Inc. - Common Stock is 3.435
When was Verrica Pharmaceuticals Inc. - Common Stock last traded?
The last trade of Verrica Pharmaceuticals Inc. - Common Stock was at 11/04/26 01:39 PM ET
What is the market capitalization of Verrica Pharmaceuticals Inc. - Common Stock?
The market capitalization of Verrica Pharmaceuticals Inc. - Common Stock is 144.12M
How many shares of Verrica Pharmaceuticals Inc. - Common Stock are outstanding?
Verrica Pharmaceuticals Inc. - Common Stock has 144M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.